This Project application is a broad collarative effort on the part of seven investigator in four institutions to study the hypothesis that opioid delta (delta) receptor subtype-selective agonist, partial agonist and antagonists may be feasible candidates for development as therapeutic agents related to the treatment of pain and addiction. These investigator bring expertise ranging from extensive experience in synthetic chemistry and molecular modeling, in pharmacological analysis of molecules in vitro and in vivo, in application of molecular techniques, to evaluation of behavior in several species including primates. Emphasis in this effort will be two-fold. First, the investigator will attempt to discover, and evaluate in several species, highly receptor subtype-selective delta ligands through a synthetic/pharmacological collaboration in order to test the underlying hypothesis. Second, the novel ligands, and other available pharmacological tools, will be employed to explore in greater detail the pharmacology and physiology of subtypes of opioid delta receptors. Strong collaborative interaction already exists and will be emphasized.
The specific aims are to: (a) synthesize novel, non-peptidic opioid delta subtype-selective ligands using state-of-the-art synthetic, analytical and modeling technology with emphasis on development of a structure- activity relationship for delta subtypes, creation of affinity ligands for characterization and localization of the receptors, and radio ligands for PET and SPECT applications; (b) to synthesize sufficient quantities of these compounds for the biological projects; (c) to evaluate the novel non-peptidic molecules for their receptors selectively in vitro and to characterize them in the Biological Evaluation Core; (d) to evaluate the pharmacology of selective novel non-peptidic agonist using approaches in vivo in antinociceptive, gastrointestinal and behavioral endpoints in mice, rats, pigeons and monkeys; (e) to determine the affinity and activity of the new compounds at the cloned opioid delta receptor(s) following transfection of the receptors to cell lines, with particular emphasis on the human delta receptor(s); (f) to determine the second messenger systems involved in the mechanisms of action of compounds acting selectively at delta receptor subtypes in the naive and opioid- exposed tissue; (g) to evaluate the pharmacology of the selective novel non-peptidic antagonists following repeated exposure alone or in combination with opioids or cocaine using place pairing and self- administration paradigms; (h) to perform detailed pharmacological studied of the possible development of physical dependence via the delta receptor; and (i) to collaborate with outside consultants to obtained any data necessary to assess the central hypothesis of potential clinical importance of opioid delta ligands. It is expected that this multidisciplinary effort will result (a) in a realistic assessment of the therapeutic potential of opioid delta receptors subtype-selective ligands, (b) in the discovery of molecules with potential for development as therapeutically useful substances, and (c) in the advancement of our understanding of the role of opioid delta receptors and their subtypes in normal and pathological physiology.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA008657-04
Application #
2331167
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1994-03-01
Project End
1999-01-31
Budget Start
1997-02-20
Budget End
1998-01-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Arizona
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Bird, M F; Vardanyan, R S; Hruby, V J et al. (2015) Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands. Br J Anaesth 114:646-56
Nair, Padma; Yamamoto, Takashi; Kulkarni, Vinod et al. (2009) Novel bifunctional peptides as opioid agonists and NK-1 antagonists. Adv Exp Med Biol 611:537-8
Martin, T J; Kim, S A; Cannon, D G et al. (2000) Antagonism of delta(2)-opioid receptors by naltrindole-5'-isothiocyanate attenuates heroin self-administration but not antinociception in rats. J Pharmacol Exp Ther 294:975-82
Lashbrook, J M; Ossipov, M H; Hunter, J C et al. (1999) Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats. Pain 82:65-72
Alfaro-Lopez, J; Okayama, T; Hosohata, K et al. (1999) Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand. J Med Chem 42:5359-68
Liao, S; Alfaro-Lopez, J; Shenderovich, M D et al. (1998) De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor. J Med Chem 41:4767-76
Bihm, C C; Williams, C L; Burks, T F (1998) Central actions of endomorphins: new endogenous opioids. Proc West Pharmacol Soc 41:81-3
Ossipov, M H; Lopez, Y; Bian, D et al. (1997) Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve-ligation injury. Anesthesiology 86:196-204
Knapp, R J; Santoro, G; De Leon, I A et al. (1996) Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. J Pharmacol Exp Ther 277:1284-91
Malatynska, E; Wang, Y; Knapp, R J et al. (1996) Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80. J Pharmacol Exp Ther 278:1083-9

Showing the most recent 10 out of 15 publications